The landscape of structural variants in male infertility identified by optical genome mapping

This study demonstrates that optical genome mapping can identify rare, potentially causative structural variants in 25% of male infertility patients that are missed by traditional diagnostic methods, offering a promising new avenue for resolving the ~70% of cases currently lacking a genetic diagnosis.

The Gist

The Big Picture: The "Missing Piece" of the Puzzle

Imagine that having a baby is like building a complex Lego castle. For the castle to stand, you need the right bricks, the right instructions, and no missing pieces.

For men who struggle to have children (male infertility), doctors have been trying to find the "missing brick" for a long time. They usually check three main things:

1. The Blueprint (Karyotyping): Looking at the big picture of the chromosomes to see if any huge chunks are missing or swapped.
2. The Special Instructions (Y-Chromosome & CFTR): Checking specific pages in the instruction manual that are known to cause problems.

The Problem: These traditional methods only find the answer about 30% of the time. For the other 70% of men, the doctors say, "We don't know why," even though there is clearly a genetic reason. It's like looking at a Lego castle and saying, "It's broken," but only being able to see the big blocks, not the tiny, broken pieces inside.

The New Tool: The "High-Definition Microscope"

This study introduces a new tool called Optical Genome Mapping (OGM).

Think of traditional genetic testing as looking at a map of a city from a plane. You can see the big highways and major districts, but you can't see the potholes in the side streets or the broken streetlights.

OGM is like a drone flying just a few feet above the ground. It can see the tiny cracks in the pavement, the missing street signs, and the complex detours that the plane couldn't see. It doesn't just look at the "letters" of the DNA code; it looks at the physical shape and structure of the DNA strands themselves.

What Did They Do?

The researchers took two groups of men:

• 88 Men with Infertility: Men who had already been tested with the old methods (the "plane view") and were told they had no obvious genetic cause.
• 132 Healthy Men: A control group to see what "normal" looks like with this new high-tech drone.

They used OGM to scan their DNA for Structural Variants (SVs).

• Analogy: If DNA is a long rope, a "Structural Variant" is when a piece of the rope is twisted (inversion), cut out (deletion), copied twice (duplication), or a knot is tied in it (insertion).

The Findings: What Did They Discover?

1. The "Noise" is the Same
First, they counted all the twists and turns in the DNA. They found that infertile men didn't have more twists and turns than healthy men. Everyone has some "messy" DNA; it's just part of being human.

2. The "Hidden Gems"
However, when they looked specifically at the critical instructions (the 265 genes known to be involved in making sperm), they found something amazing.

• 25% of the infertile men had rare, unique "typos" or "tears" in these specific instructions that the healthy men did not have.
• 5.6% of the men had a "smoking gun"—a specific tear in the DNA that was almost certainly the cause of their infertility.

3. The Two Big Breakthroughs
The study found two specific cases that traditional tests would have completely missed:

• Case A (The Missing Page): One man had a tiny chunk of DNA missing from a gene called SPAG1. This gene is like a quality control inspector for sperm. Without it, the sperm can't swim properly. Traditional tests were too "blurry" to see this tiny missing page, but OGM spotted it immediately.
• Case B (The Knot): Another man had a "knot" (an expansion) in a gene called DMPK. This is associated with a muscle disease, but in his case, it was mild and only showed up as infertility. Traditional tests look for specific patterns and missed this knot entirely.

Why Does This Matter?

Imagine you are a mechanic trying to fix a car that won't start.

• Old Method: You check the battery and the gas tank. If those are fine, you give up and say, "It's just a bad luck car."
• New Method (This Study): You use a new scanner that finds a tiny, broken wire inside the engine that no one knew about. Now, you can fix it.

The Takeaway:
This study shows that Optical Genome Mapping is a game-changer. It can find the "hidden broken wires" in the DNA of men who were previously told they had no genetic explanation for their infertility.

While we can't yet say exactly how every single one of these new findings causes infertility (some are still a mystery), the study proves that we are now able to see problems that were previously invisible. This opens the door to diagnosing more men, understanding the true causes of infertility, and potentially offering better treatments or genetic counseling in the future.

In a Nutshell

We used a super-powerful microscope to look at the DNA of men with infertility. We found that while their DNA isn't "messier" overall, they do have specific, tiny structural errors in the "sperm-making" instructions that regular tests miss. This means we can finally start solving the mystery for the 70% of men who were previously left without answers.

Technical Summary

1. Problem Statement

Male infertility (MI) affects approximately 2.5–12% of men, yet current standard diagnostic protocols (karyotyping, Y-chromosome microdeletion testing, and CFTR gene analysis) only identify a genetic cause in roughly 30% of cases. The remaining 70% are often classified as idiopathic.

• The Gap: While research has identified over 265 genes potentially involved in male fertility, the role of Structural Variants (SVs)—specifically balanced translocations, inversions, complex rearrangements, and small insertions/deletions that fall below the resolution of karyotyping (5–10 Mb) or are missed by standard Next-Generation Sequencing (NGS) and microarrays—remains largely unexplored.
• The Challenge: Existing variant interpretation guidelines (ACMG/ClinGen) are optimized for Single Nucleotide Variants (SNVs) and Copy Number Variants (CNVs), making the classification of complex SVs difficult, especially given the lack of fertility status data in public reference databases.

2. Methodology

The study employed a longitudinal case-control design to evaluate the utility of Optical Genome Mapping (OGM) in detecting SVs associated with MI.

• Cohort:
  • Cases: 88 male infertility patients (negative for standard karyotype, Y-microdeletion, and CFTR testing).
  • Controls: 132 healthy males (45 healthy fathers, 87 partners with recurrent miscarriage but normal sperm quality).
• Technology:
  • Platform: Bionano Saphyr instrument using DLE-1 SP-G2 chemistry.
  • Sample: High-molecular-weight DNA extracted from whole blood.
  • Analysis Pipeline: De novo assembly and variant annotation via Bionano Solve 3.7; visualization and filtering via Bionano Access 1.7.2.
• Filtering Strategy:
  • Variants were filtered against a custom panel of 265 genes associated with male fertility, plus specific AZFa/b/c regions on the Y chromosome.
  • Variants were retained if they had a population frequency <10% and were absent (0% frequency) in the internal Bionano manufacturer dataset.
  • Manual curation was performed to assess overlap with biological processes relevant to MI.
• Validation:
  • OGM findings were validated using orthogonal methods: Whole Exome Sequencing (WES), long-range PCR, and targeted PCR (e.g., Devyser kits for Y-deletions).
• Reference Genome: GRCh38.

3. Key Contributions

• First Comprehensive OGM Survey in MI: This is the first study to comprehensively map the landscape of structural variants in a large cohort of male infertility patients using OGM, moving beyond traditional cytogenetics.
• Discovery of "Hidden" Variants: The study demonstrates that OGM can detect complex SVs (inversions, insertions, amplifications) that are invisible to standard clinical testing and often missed by WES due to intronic breakpoints or repetitive regions.
• Refinement of Diagnostic Yield: The authors identified specific pathogenic mechanisms that would have been missed by current standard-of-care guidelines, effectively increasing the diagnostic yield for a subset of patients.

4. Key Results

• Global SV Burden: There was no significant difference in the total number of structural variants between MI patients (avg. 4,220 SVs) and healthy controls (avg. 4,322 SVs). This suggests that MI is not caused by a general genomic instability but rather by specific, rare pathogenic rearrangements.
• Rare Variants in MI Genes:
  • 25.0% of MI patients (22/88) carried rare SVs overlapping fertility-associated genes that were absent in the control group.
  • In contrast, only 17.4% of controls carried such rare variants.
• Likely Causative Findings (5 cases, 5.6% of cohort):
  1. SPAG1 Deletion: A 12.1 kb deletion in SPAG1 (and FBXO43), confirmed by WES. This is a known cause of primary ciliary dyskinesia and infertility.
  2. DMPK Expansion: A 1.3 kb insertion/expansion in the 3' UTR of DMPK, confirmed as a pathogenic CTG repeat expansion (Myotonic Dystrophy Type 1) via targeted testing. This was missed by standard OGM assembly but flagged as an SV.
  3. Three Y-Chromosome Microdeletions: Detected by OGM but initially missed by standard Devyser PCR kits, highlighting OGM's superior sensitivity in complex Y regions.
• Variants of Uncertain Significance (VUS):
  • 16 additional rare SVs were found exclusively in the MI cohort, including large inversions (e.g., 8.6 Mb on 20q), complex duplications, and amplifications on the X chromosome.
  • These variants are likely too small for karyotyping and too complex for standard NGS, representing a new frontier for genetic investigation.

5. Significance and Limitations

Significance:

• Diagnostic Expansion: The study proves that OGM can resolve ~5.6% of "idiopathic" male infertility cases that standard testing misses, specifically by identifying complex rearrangements and expansions.
• New Research Avenues: It highlights a pool of rare SVs (inversions, amplifications) in fertility genes that require further functional characterization to establish causality.
• Methodological Shift: It advocates for the integration of OGM into the diagnostic algorithm for male infertility, particularly for patients with negative standard workups.

Limitations:

• Interpretation Challenges: Current ACMG/ClinGen guidelines are not fully adapted for complex SVs (e.g., balanced translocations, inversions), making pathogenicity classification difficult.
• Technical Blind Spots: OGM cannot label centromeric/telomeric regions (missing Robertsonian translocations) and struggles with exact breakpoint resolution in highly repetitive regions like the Y chromosome.
• Control Data: The fertility status of individuals in public databases (GnomAD, DGV) is unknown, complicating the application of "rarity" criteria for variant classification.
• Validation: Some small intragenic variants required manual inspection of raw WES data for confirmation, indicating that OGM and WES are complementary rather than mutually exclusive.

Conclusion:
The study concludes that while the overall SV burden is similar between infertile and fertile men, Optical Genome Mapping is a powerful tool for identifying rare, complex, and clinically relevant structural variants in male infertility that are currently undetectable by standard clinical genetics. This opens a new avenue for diagnosing the "missing" 70% of male infertility cases.